Herantis Pharma

Herantis Pharma is a biopharmaceutical company focused on developing innovative therapies for diseases with high unmet medical needs. The company is based in Finland and was founded in 2008.

Herantis Pharma is primarily focused on developing treatments for neurodegenerative diseases and fibrotic diseases. Their pipeline includes investigational drugs targeting diseases such as Parkinson's disease, Alzheimer's disease, and secondary lymphedema.

Herantis Pharma, which has been traded on Nasdaq Helsinki since 2014, intends to cure the underlying causes of diseases that are challenging to treat as well as their symptoms. The most advanced programme of the company is a gene therapy for breast cancer-associated lymphedema, an abnormal swelling that can arise from cancer treatments. It is currently in phase II. A Parkinson's disease treatment that aims to prevent neurons from deteriorating and to regenerate those that have already been harmed is also being tested by Herantis in phase I/II clinical trials.

Headquarters: Espoo

Founded: 2008

Website: https://herantis.com/